Example: biology

795 PHARMACEUTICAL COMPOUNDING—NONSTERILE …

Revision BulletinOfficial January 1, 2014 795 pharmaceutical compounding nonsterile Preparations1 Preparation of drugs or devices for the purposes of, or 795 PHARMACEUTICALas an incident to, research (clinical or academic),teaching, or chemical analysisCOMPOUNDING nonsterile Preparation of drugs and devices for prescriber s officeuse where permitted by federal and state lawPREPARATIONSHAZARDOUS DRUG Any drug identified by at least one ofthe following six criteria: Carcinogenicity Teratogenicity or developmental toxicity Reproductive toxicity in humansINTRODUCTION Organ toxicity at low doses in humans or animals GenotoxicityThe purpose of this chapter is to provide compounders New drugs that mimic existing hazardous drugs inwith guidance on applying good compounding practicesstructure or toxicity [for examples see current Nationalfor the preparation of nonsterile compounded formulationsInstitute for Occupational Safety and Health (NIOSH)for dispensing and/or admini]

tive ingredient in that preparation and furnishing pharma-specified limits and throughout its period of storage and cological activity or other direct effect in the diagnosis, use, the same properties and characteristics that it pos-cure, mitigation, treatment, or prevention of disease in sessed at the time of compounding (see Stability Considera-

Tags:

  Pharmaceutical, Ingredients, Nonsterile, Compounding, 795 pharmaceutical compounding nonsterile

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of 795 PHARMACEUTICAL COMPOUNDING—NONSTERILE …

1 Revision BulletinOfficial January 1, 2014 795 pharmaceutical compounding nonsterile Preparations1 Preparation of drugs or devices for the purposes of, or 795 PHARMACEUTICALas an incident to, research (clinical or academic),teaching, or chemical analysisCOMPOUNDING nonsterile Preparation of drugs and devices for prescriber s officeuse where permitted by federal and state lawPREPARATIONSHAZARDOUS DRUG Any drug identified by at least one ofthe following six criteria: Carcinogenicity Teratogenicity or developmental toxicity Reproductive toxicity in humansINTRODUCTION Organ toxicity at low doses in humans or animals GenotoxicityThe purpose of this chapter is to provide compounders New drugs that mimic existing hazardous drugs inwith guidance on applying good compounding practicesstructure or toxicity [for examples see current Nationalfor the preparation of nonsterile compounded formulationsInstitute for Occupational Safety and Health (NIOSH)]

2 For dispensing and/or administration to humans or ] compounding is an integral part of pharmacy practice andMANUFACTURING The production, propagation, conversion,is essential to the provision of healthcare. This chapter andor processing of a drug or device, either directly or indi-applicable monographs on formulation help define goodrectly, by extraction of the drug from substances of naturalcompounding practices. Furthermore, this chapter providesorigin or by means of chemical or biological information to enhance the compounder s ability inManufacturing may also include any packaging or repack-the compounding facility to extemporaneously compoundaging of the substance(s) or labeling or relabeling of con-preparations that are of acceptable strength, quality, andtainers for resale by pharmacies, practitioners, or other per-purity.

3 Pharmacists, other healthcare professionals, engaged in the compounding of drug preparationsPREPARATION For the purposes of this chapter, a com-should comply with applicable state and federal com-pounded drug dosage form or dietary supplement or a de-pounding laws, regulations, and to which a compounder has introduced a drug. Thisterm will be used to describe compounded formulations;the term product will be used to describe manufacturedDEFINITIONS PHARMACEUTICAL dosage forms. (For the definitions of officialsubstance and official products, see General Notices and Re-ACTIVE PHARMACEUTICAL INGREDIENT (API) Any substance orquirements.)mixture of substances intended to be used in the com-STABILITY The extent to which a preparation retains, withinpounding of a drug preparation, thereby becoming the ac-specified limits and throughout its period of storage andtive ingredient in that preparation and furnishing pharma-use, the same properties and characteristics that it pos-cological activity or other direct effect in the diagnosis,sessed at the time of compounding (see Stability Considera-cure, mitigation, treatment, or prevention of disease intions in Dispensing Practice 1191 , the table Criteria for Ac-humans and animals or affecting the structure and functionceptable Levels of Stability)

4 Of the A component for internal or external use that isADDED SUBSTANCES ingredients that are necessary to com-used as a carrier or diluent in which liquids, semisolids, orpound a preparation but are not intended or expected tosolids are dissolved or suspended. Examples include, butcause a pharmacologic response if administered alone inare not limited to, water, syrups, elixirs, oleaginous liquids,the amount or concentration contained in a single dose ofsolid and semisolid carriers, and proprietary compounded preparation. The term is used synony-mously with the terms inactive ingredients , excipients, andpharmaceutical OF COMPOUNDINGBEYOND-USE DATE (BUD) The date after which a com-pounded preparation should not to be used.

5 DeterminedIn the three general categories of nonsterile compound-from the date the preparation is described in this section, different levels of experience,COMPONENT Any ingredient used in the compounding of atraining, and physical facilities are associated with eachdrug preparation, including any active ingredient or that is used in its used to determine overall classification include:COMPOUNDER A professional authorized by the appropriate degree of difficulty or complexity of the compoundingjurisdiction to perform compounding pursuant to a pre-processscription or medication order by a licensed prescriber. stability information and warnings packaging and storage requirementsCOMPOUNDING The preparation, mixing, assembling, alter- dosage formsing, packaging, and labeling of a drug, drug-delivery de- complexity of calculationsvice, or device in accordance with a licensed practitioner s local versus systemic biological dispositionprescription, medication order, or initiative based on the level of risk to the compounderpractitioner/patient/pharmacis t/compounder relationship in potential for risk of harm to the patientthe course of professional practice.

6 compounding includesSee PHARMACEUTICAL compounding Sterile Preparationsthe following: 797 for risk levels associated with sterile preparations. Preparation of drug dosage forms for both human andSpecialty areas such as radiopharmaceuticals require specialanimal patientstraining and are beyond the scope of this chapter. Com- Preparation of drugs or devices in anticipation of pre-pounders shall acquire and maintain knowledge and skillsscription drug orders based on routine, regularly ob-in all areas ( , dosage form, patient population, andserved prescribing patternsmedical specialty) for which they compound. Reconstitution or manipulation of commercial productsthat may require the addition of one or moreingredients 2013 The United States Pharmacopeial ConventionAll Rights Bulletin2 795 pharmaceutical compounding nonsterile PreparationsOfficial January 1, 2014(OSHA) hazard communication labels (see ), and Material Safety Data Sheets (MSDSs) areDescription of Categoriesavailable to compounding personnel for all drugsand chemicals used in Making a preparation that has a United equipment used in compounding is clean, prop-Pharmacopeia (USP)

7 compounding monograph or that ap-erly maintained, and used in a peer-reviewed journal article that contains compounding environment is suitable for its in-cific quantities of all components, compounding proceduretended purpose; and procedures are implemented toand equipment, and stability data for that formulation withprevent cross-contamination, especially when com-appropriate BUDs; or reconstituting or manipulating com-pounding with drugs ( , hazardous drugs andmercial products that may require the addition of one orknown allergens like penicillin) that require specialmore ingredients as directed by the manufacturer. include Captopril Oral Solution, Indomethacin authorized personnel are allowed in the imme-Gel, and Potassium Bromide Oral Solution, vicinity of the drug compounding Making a preparation that requires is assurance that processes are always carriedcalculations or procedures (such as calibration of dosageout as intended or specified and are mold cavities) to determine quantities of conditions and procedures are ade-per preparation or per individualized dosage units; or mak-quate for preventing a preparation for which stability data for that aspects of compounding are appropriatelyformulation are not available.

8 Examples include Suppositories, diphenhydramine procedures and records exist for investigat-troches, and mixing two or more manufactured creaming and correcting failures or problems in com-products when the stability of the mixture is not , testing, or the preparation Making a preparation that requires specialtraining, environment, facilities, equipment, and proceduresCOMPOUNDING PROCESSto ensure appropriate therapeutic outcomes. Examples ofpossible complex preparation types include transdermalThe compounder is responsible for ensuring that eachdosage forms, modified-release preparations, and some in-individual incidence of compounding meets the criteriaserts and suppositories for systemic in this section (additional information on these crite-ria is provided in the sections that follow).

9 RESPONSIBILITIES OF THE COMPOUNDERC riteria When compounding Each DrugThe compounder is responsible for compounding prepa-Preparationrations of acceptable strength, quality, and purity and inaccordance with the prescription or medication order. dose, safety, and intended use of the prepara-compounder is also responsible for dispensing the finishedtion or device has been evaluated for suitability inpreparation, with appropriate packaging and labeling, andterms of:in compliance with the requirements established by the ap- the chemical and physical properties of theplicable state agencies, state boards of pharmacy, federalcomponentslaw, and other regulatory agencies where appropriate.

10 Indi- dosage formviduals who are engaged in drug or dietary supplement therapeutic appropriateness and route of adminis- compounding shall be proficient in compounding andtration, including local and systemic biologicalshould continually expand their compounding knowledgedispositionby participating in seminars and/or studying appropriate legal limitations, if anyliterature. They shall be knowledgeable about the Master Formulation Record should be createdof this chapter and should be familiar with Pharmaceuticalbefore compounding a preparation for the first Sterile Preparations 797 , PharmaceuticalThis record shall be followed each time that prepara-Dosage Forms 1151 , PHARMACEUTICAL Calculations in Prescrip-tion is made.


Related search queries